Here's some of what is coming soon to NeurologyLive® this week.
News|Articles|May 9, 2025
FDA Action Update, April 2025: Approvals, Expansion, and Authorization
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology news headlines you may have missed over the course of April 2025, compiled all into one place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in April 2025, making a number of decisions on potential new therapeutic agents including granting approvals, an clearance, an expanded indication, and an authorization.
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
Advertisement
Advertisement